TRNS vs. MIR, TXG, CTKB, LAB, EYPT, AEHR, SENS, ALNT, QTRX, and QSI
Should you be buying Transcat stock or one of its competitors? The main competitors of Transcat include Mirion Technologies (MIR), 10x Genomics (TXG), Cytek Biosciences (CTKB), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Senseonics (SENS), Allient (ALNT), Quanterix (QTRX), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry.
Transcat vs.
Transcat (NASDAQ:TRNS) and Mirion Technologies (NYSE:MIR) are both computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Transcat has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Mirion Technologies has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
In the previous week, Mirion Technologies had 1 more articles in the media than Transcat. MarketBeat recorded 2 mentions for Mirion Technologies and 1 mentions for Transcat. Transcat's average media sentiment score of 0.94 beat Mirion Technologies' score of 0.67 indicating that Transcat is being referred to more favorably in the media.
Transcat received 194 more outperform votes than Mirion Technologies when rated by MarketBeat users. However, 84.21% of users gave Mirion Technologies an outperform vote while only 66.88% of users gave Transcat an outperform vote.
98.3% of Transcat shares are owned by institutional investors. Comparatively, 78.5% of Mirion Technologies shares are owned by institutional investors. 2.3% of Transcat shares are owned by company insiders. Comparatively, 2.2% of Mirion Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Transcat currently has a consensus target price of $130.25, suggesting a potential upside of 29.81%. Mirion Technologies has a consensus target price of $19.25, suggesting a potential upside of 16.43%. Given Transcat's higher probable upside, analysts clearly believe Transcat is more favorable than Mirion Technologies.
Transcat has a net margin of 6.63% compared to Mirion Technologies' net margin of -7.84%. Transcat's return on equity of 7.36% beat Mirion Technologies' return on equity.
Transcat has higher earnings, but lower revenue than Mirion Technologies. Mirion Technologies is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.
Summary
Transcat beats Mirion Technologies on 11 of the 18 factors compared between the two stocks.
Get Transcat News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Transcat Competitors List
Related Companies and Tools
This page (NASDAQ:TRNS) was last updated on 1/18/2025 by MarketBeat.com Staff
Free TRNS Stock Alerts